Bayer Signs an Exclusive License Agreement with Kyoto University for Pulmonary Disorders
Shots:
- Bayer and Kyoto University collaborate to jointly conduct clinical trials for identifying targets in lung diseases. Bayer will have an exclusive option to license the developed product in the trial
- The focus of the agreement is to discover targets and develop treatments- with combined techniques of the company in pulmonary disorders including idiopathic pulmonary fibrosis (IPF)
- In 2014- Bayer and Kyoto University's Office of Society-Academia Collaboration for Innovation (KU-SACI) collaborated to jointly explore candidates for certain research projects in areas cardiology & oncology including hematology- gynecology- and ophthalmology
Ref: Bayer | Image: Bayer
Tags
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
